MikeTrendsTrends right now

search

brain cancer

Trends

  1. 1
    13-Year-Old Becomes First Cured of DIPG Brain Cancer●A 13-Year-Old Has Been Cured of DIPG, the Deadliest Childhood Brain CancerYhnWorld138 min ago

    A 13-year-old child has reportedly become the first patient cured of diffuse intrinsic pontine glioma, an aggressive childhood brain tumour with a near-uniformly fatal prognosis. The case, described as a world first, is drawing attention from clinicians and families because DIPG has resisted decades of treatment attempts, and any confirmed cure would mark a major breakthrough in paediatric oncology.

  2. 2
    Proliferative Pause Offers Window to Prevent Brain Metastasis●Proliferative Pause Reveals Window to Prevent Brain Metastasis✉newsHealthMedicine39 min ago

    Researchers report that a 'proliferative pause' — a dormant phase some cancer cells enter before spreading to the brain — may offer a critical window to intervene and stop brain metastasis before it begins. The finding could shape new strategies for preventing one of the deadliest complications of cancer, and is drawing attention from oncology and precision medicine communities.

  3. 3

    Angela Stribling, a host known for her work on BET, has died following a battle with brain cancer. Details about her age, the date of her death, and her full career have not yet been widely reported. Viewers and colleagues are expected to share tributes to the longtime television personality as news of her death spreads.

  4. 4
    Mount Sinai to test novel liquid radioembolic agent for brain tumors●Mount Sinai announces collaborative research agreement to evaluate novel liquid radioembolic agent for brain tumors✉newsHealthMedicine2 h ago

    Mount Sinai has announced a collaborative research agreement to evaluate a novel liquid radioembolic agent for treating brain tumors. The therapy would deliver radiation directly to tumor tissue in liquid form, an approach being explored for cancers that are difficult to treat surgically. Details on the partner institution, trial design and timeline have not yet been released, and clinical results remain pending.